Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of patients with rheumatoid arthritis (RA), who do not respond to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). The gene discussed is TNF; the disease is rheumatoid arthritis.